US Stock Futures Hold Steady Ahead of CPI Data and Iran Conflict Concerns 
Rubio Discusses Iran Crisis and Strait of Hormuz Disruptions With UK and Australia 
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge 
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
KOSPI Hits Record High as AI Chip Demand Boosts Samsung and SK Hynix 
Ibiden Stock Surges as AI Chip Demand Boosts Profit Outlook 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Pfizer Inc.’s planned delivery of critical new medicines, such as respiratory syncytial virus (RSV) vaccine, to low-income nations, is likely to be delayed by several years due to several issues.
According to global health officials, Pfizer has not yet taken some of the necessary actions to make the vaccine accessible in developing nations.
They include getting the shot approved by the WHO and by nonprofit organizations that finance purchases in low-income countries, such as the global vaccine alliance Gavi.
Furthermore, the health agency prefers syringes that are automatically disabled after one injection for safety reasons to prevent reuse, but Pfizer's RSV vaccine is not made for those syringes.
Additionally, the RSV shot is only presently offered in single-dose vials. Multi-dose vials are frequently utilized in situations with less resources since they are less expensive and easier to distribute.
Preservatives must be added to multi-dose vials, therefore the manufacturer must do further tests to make sure there will be no impact on the vaccine's safety or effectiveness.
The vaccine will need a different delivery system to be used in developing countries in Africa and Asia, including alternative packaging and syringes.
Preparations for those modifications are just beginning, according to the World Health Organization.
Pfizer committed to more equitable access last year, following criticism that it prioritized wealthy nations for doses of its COVID-19 shot early in the pandemic. The company says it wants to shorten a timeline in which poorer countries often get vaccines many years after they are available elsewhere.
The drugmaker received a $28 million grant from the Bill and Melinda Gates Foundation in September to support the launch of the RSV vaccine in poorer countries, where RSV, a common cold-like virus, is much more likely to be lethal for very young children.
Pfizer's maternal RSV vaccine is expected to be approved for use in pregnant women in August in the US and several months later in Europe. Its peak sales forecast is more than $2 billion annually, together with the maternal vaccine and an RSV shot for older adults.
